{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:39:46Z","timestamp":1702730386128},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoporosis is a common skeletal disorder, often leading to fragility fracture. Combination therapy with raloxifene, a selective estrogen receptor modulator, and cholecalciferol (vitamin D<jats:sub>3<\/jats:sub>) has been proposed to improve the overall efficacy and increase compliance of raloxifene therapy for postmenopausal osteoporosis. To our knowledge, there has been no report of any study on the pharmacokinetic interaction between raloxifene and cholecalciferol. This study aimed to evaluate the possible pharmacokinetic interactions between raloxifene and cholecalciferol in healthy adult male Korean volunteers. Twenty subjects completed this open\u2010label, randomized, single\u2010dose, 3\u2010period, 6\u2010sequence, crossover phase 1 study with a 14\u2010day washout period. Serial blood samples were collected from 20 hours before dosing to 96 hours after dosing. The plasma concentrations of raloxifene and cholecalciferol were determined using a validated method for high\u2010performance liquid chromatography with tandem mass spectrometry. The geometric mean ratios (90%CIs) for area under the plasma concentration\u2013time curve from time 0 to the last quantifiable time point and maximum plasma concentration of raloxifene with or without cholecalciferol were 1.02 (0.87\u20101.20) and 0.87 (0.70\u20101.08), respectively. For baseline\u2010corrected cholecalciferol, geometric mean ratios (90%CIs) of area under the plasma concentration\u2013time curve from time 0 to the last quantifiable time point and maximum plasma concentration with or without raloxifene were 1.01 (0.93\u20101.09) and 0.99 (0.92\u20101.06), respectively. Concurrent treatment with raloxifene and cholecalciferol was generally well tolerated. These results suggest that raloxifene and cholecalciferol have no clinically relevant pharmacokinetic drug\u2010drug interactions when administered concurrently. All treatments were well tolerated, with no serious adverse events.<\/jats:p>","DOI":"10.1002\/cpdd.1062","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T03:49:43Z","timestamp":1641354583000},"page":"623-631","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers"],"prefix":"10.1002","volume":"11","author":[{"given":"Hae Won","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Youl","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wookjae","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u2010Ri","family":"Gwon","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyunghee","family":"Cho","sequence":"additional","affiliation":[{"name":"Analytical Research Division Biocore Co. Ltd.  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Backhwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Development Alvogen Korea Co. Ltd.  Seoul Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook Jin","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young\u2010Ran","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine Kyungpook National University  Daegu Republic of Korea"},{"name":"Department of Clinical Pharmacology Kyungpook National University Hospital  Daegu Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S131023"},{"issue":"6","key":"e_1_2_8_3_1","first-page":"S164","article-title":"Osteoporosis and the burden of osteoporosis\u2010related fractures","volume":"17","author":"Dempster DW","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_4_1","first-page":"92","article-title":"Osteoporosis: a review of treatment options","volume":"43","author":"Tu KN","year":"2018","journal-title":"P.T."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2794-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(99)00176-9"},{"issue":"4","key":"e_1_2_8_7_1","first-page":"1131","article-title":"Raloxifene: a selective estrogen receptor modulator","volume":"60","author":"Scott JA","year":"1999","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano10061085"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8750"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060020-00013"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/57.18.1669"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2012.03.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2015.09.001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(98)00278-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03363.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-76"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci096"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.31"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010382010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114512001675"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201800956R"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.149815"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.081612"},{"key":"e_1_2_8_24_1","volume-title":"Endotext [internet]","author":"Lewiecki EM","year":"2000"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200504060-00006"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.958"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchromb.2014.05.006","article-title":"Development and validation of an LC\u2010MS\/MS based method for quantification of 25 hydroxyvitamin D2 and 25 hydroxyvitamin D3 in human serum and plasma","volume":"96","author":"Zhang SW","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"e_1_2_8_28_1","first-page":"61","article-title":"Development and validation of a UPLC\u2010MS\/MS assay for simultaneous estimation of raloxifene and its metabolites in human plasma","volume":"4","author":"Jadhav DH","year":"2012","journal-title":"J Bioanal Biomed"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.12.001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.1.149"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1746-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9787-1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495062"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1477"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1524-y"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:30:52Z","timestamp":1693006252000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/cpdd.1062"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1062","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"2021-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}